Evolve

A global phase 2 clinical trial for people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease

Status
Start Date
Condition
Estimated
enrollment
Age Range
Phase
Study Type

Objective

To assess the safety of an investigational drug, aducanumab in people with mild cognitive impairment due to Alzheimer’s disease, or mild Alzheimer’s disease.

The investigational drug

Aducanumab (BIIB037) is a human recombinant monoclonal antibody (mAb). It is thought that aducanumab may have the potential to reduce harmful amyloid plaques (abnormal deposits) that form in the brains of people with Alzheimer’s disease, possibly slowing the progress of the disease.

Key eligibility criteria

  • Men and women
  • 50-85 years old
  • Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Do not have other significant/uncontrolled medical issues
  • Are able to undergo multiple Magnetic Resonance Imaging (MRI) tests of the brain
  • Have a study partner or caregiver who can attend at least one screening appointment and provide information about their health

Trial length

  • Approximately 1 year 6 months
  • Optional potential long-term extension study